NEWS

U.S. Court of Appeals for Federal Circuit says Johnson's worldwide best-selling schizophrenia drug patent may be invalid

Release time:

2024-04-12 13:41

 

 

Invega Sustenna, which is used to treat schizophrenia, is the best-selling drug of Jiusheng Company. Last year, Invega Sustenna-related drugs sold more than US $4.1 billion worldwide. Jiao Sheng Company (Johnson & Johnson) sued Teva Pharmaceutical Company (TEVA.TA) and Mylan Pharmaceutical Company (Mylan N.V.)(incorporated into Viatris Inc., a health care company) in 2018 and 2019 respectively, saying that the drugs produced and sold by Teva Company and Mylan Company infringed their Invega Sustenna drug patents.

 

In 2021, the U.S. District Court ruled that Teva could not prove that Jiao Sheng's Invega Sustenna drug patent was invalid. Upon appeal by Teva, the U.S. Federal Circuit Court of Appeals accepted Teva's claim that Jiao Sheng's Invega Sustenna drug patent was invalid and returned the case to the district court on April 1, 2024 to rehear whether Jiao Sheng's Invega Sustenna drug patent was invalid.

 

A spokesman for the company said it would continue to defend the intellectual property rights of Invega's Sustenna drug.